Molecular diagnostic method for dementia with lewy bodies
AssigneeOryzon Genomics, S.A.
InventorsTamara Maes, Carlos Buesa Arjol, Marta Barrachina Castillo, Isidro Ferrer Abizanda
Life of this patent
Estimating the term…
Abstract
The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.
Claims1
A method of diagnosing dementia with Lewy bodies (DLB) in a subject, the method comprising:
- obtaining a sample from the subject's frontal cortex;
- and
- analyzing the level of expression of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene in the sample, wherein reduced levels of expression of UCH-L1 gene compared to controls is diagnostic of DLB, as determined by comparing the level of expression of UCH-L1 gene in the sample to UCH-L1 gene expression levels in Alzheimer's Disease (AD) and Parkinson's disease (PD).
Dependencies are inferred from the claim text.